Protalix Biotherapeutics Inc

PLX is in a clear downtrend, trading below all major EMAs with sequential lower highs and lower lows. Despite oversold RSI, there is no visible exhaustion or sustained repair, and declining volume remains dominant. The medium-term bearish bias is reinforced by price action, supporting a Sell Now approach into any bounce or EMA retest.

• ↑Q1 EPS $0.22 vs -$0.01 consensus (2278% surprise) indicates operational strength
• ↑2026 revenue guidance $78–$83M; El Fabrio targets 15–20% of $3.2B Fabry market
• ↓Q1 product revenues fell to $7.4M from $10M YoY, reflecting volatile sales